Aprea (APRE): Price-to-Revenue Ratio

Brandmark of aprea.com (APRE)

Aprea Therapeutics (APRE) bases its resilience on the development of advanced DNA repair inhibitors to combat resistant tumors. The historical P/S chart confirms market expectations, where 621.00 represents the current level of the metric. Professional management is implementing precision medicine principles, while independence from macro cycles is ensured by internal clinical trial milestones and the future commercialization of drugs.

APRE Aprea Therapeutics, Inc. P/S Multiple (08/20/2023 - 11/05/2026)

Aprea Therapeutics (APRE) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price aprea.com|APRE - Price Target Chart
- stock exchange capitalization data:
Market Value Aprea|APRE - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Aprea Therapeutics|APRE - Book Capitalization|Market Value to Equity Ratio aprea.com|APRE - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Aprea Therapeutics|APRE - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital aprea.com|APRE - Company Total Debt|Debt to Book Capital Aprea|APRE - Company Long-Term Debts|Company Short-Term Loans and Borrowings Aprea Therapeutics|Immediate Liquidity aprea.com
- earnings and multiples data:
APRE - Company Net Income|Expected Net Income Aprea Therapeutics|APRE - P/E Multiple|Forward P/E Multiple aprea.com|APRE - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Aprea|APRE - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Aprea Therapeutics|APRE - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth aprea.com|APRE - Earnings per share growth in current year|Net earnings per share change forecast for next year Aprea Therapeutics
- issuer revenue and sales details:
APRE - Company Revenue|Company Future Revenue aprea.com|APRE - P/S Multiple|Market Cap to Future Revenue Ratio Aprea
Summary company analytics:Aprea Therapeutics Inc.
Mass-produced product of Aprea Therapeutics, Inc.

As a biotechnology oncology startup implementing green chemistry principles, Aprea Therapeutics (APRE) is valued by the market using the price-to-sales ratio. This metric determines the cost of each unit of revenue, allowing investors to separate speculative overheating from the actual scale of the business. By analyzing the P/S ratio of Aprea Therapeutics, one can identify an entry point that minimizes the risk of overpayment while accounting for potential growth in operational efficiency.

Competing companies

INCY - Price to Sales|Price-to-Revenue Ratio HUTCHMED HCM|Nuvation Bio Inc - Price-to-Revenue Ratio|DAWN - Price-to-Revenue Ratio|Price to Sales Monopar Corp|INBX: P/S Multiple|Price-to-Revenue Multiple I-Mab Biopharma IMAB|Market Cap to Revenue FENC|Price to Sales Heron Therapeutics Inc HRTX|Market Cap to Revenue NVCT (Nuvectis)|CHRS (Coherus BioSciences, Inc) - Market Capitalization-to-Revenue Ratio|Corbus Pharmaceuticals - Market Cap to Revenue|Market Cap to Sales Volume CRDF (Cardiff Oncology Inc.)|BeyondSpring - P/S Multiple|Market Capitalization-to-Revenue Ratio BCAB (BioAtla, Inc.)|LIXT: P/S Multiple|Price to Sales Citius Pharmaceuticals, Inc. (CTXR)|Price-to-Revenue Ratio Cellectar Biosciences|BLRX: Market Capitalization-to-Revenue Ratio|P/S Multiple CANF|P/S Multiple kaziatherapeutics.com (KZIA)|Price-to-Revenue Ratio Silexion Therapeutics SLXN|NCNA (NuCana PLC) - Price-to-Sales Ratio|CMRX: Market Cap to Revenue|Price to Sales cyclacel.com|GTHX: P/S Multiple|Kronos Bio Inc (KRON) - P/S Multiple|Price-to-Revenue Ratio Kintara|Oncternal Corp - Price-to-Sales Ratio|Price-to-Revenue Ratio Portage Biotech Inc. (PRTG)